Followers | 248 |
Posts | 27083 |
Boards Moderated | 1 |
Alias Born | 08/26/2015 |
Sunday, February 19, 2017 5:38:41 PM
Historically, the company has not had a revenue stream. BIEI has several key patents pending. The most notable patent is for a cancer treatment, which outperformed other leading cancer treatments in laboratory testing. The next test of this treatment will be on humanized mice. Due to the cost of testing, the company wanted to sell oral pain relief treatments to generate revenue. The FDA testing for an oral treatment would cost upwards of a million dollars and a year or two in time. The company decided to change to topical treatments, which do not require FDA approval.
The company did have a burn rate of $100,000 a month and had a settlement of $300,000, causing dilution of stock. The current OS is approximately 400,000,000.
The products sold currently by PBPMS are a 96-hour patch and roll-on CBD oil. The patch has CBD and other natural ingredients. These products appear to be better than competing brands. Other products will be available later.
The P/Es are not available yet for PBPMS since the website launched less than one month ago. The number of orders generated so far is approximately 400. No average order dollar amount is available. The company has agreements with wellness centers and a small retail chain for product distribution. More points of sale agreements are expected.
The CEO, William Hartman, has had several recent interviews that provide considerable information. Look for Uptick interviews.
What should investors expect?
Dilution should end soon.
With the absence of dilution, the stock price per share should increase to reflect a realistic market cap.
Sales of products should increase, since reviews are very positive and points of sale will increase.
Last 10Q: http://www.discountedgar.com/data/biei/filesUploaded/biei10q033116.pdf
Company website: http://www.premierbiomedical.com/
PBPMS website: http://painreliefmeds.com/
Uptick: https://upticknewswire.com/tag/biei/
Facebook: https://www.facebook.com/Bieiotc/
Twitter: @bieiotc #pain #painreliefmeds
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM